Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems

被引:35
作者
Abdellatif, Ahmed A. H. [1 ,2 ]
Tawfeek, Hesham M. [3 ]
Abdelfattah, Ahmed [3 ]
Batiha, Gaber El-Saber [4 ]
Hetta, Helal F. [5 ,6 ]
机构
[1] Qassim Univ, Coll Pharm, Dept Pharmaceut, Buraydah 51452, Saudi Arabia
[2] Al Azhar Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Assiut 71524, Egypt
[3] Assiut Univ, Fac Pharm, Dept Ind Pharm, Assiut 71526, Egypt
[4] Damanhour Univ, Fac Vet Med, Dept Pharmacol & Therapeut, Damanhour 22511, Albeheira, Egypt
[5] Assiut Univ, Fac Med, Dept Med Microbiol & Immunol, Assiut 71526, Egypt
[6] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA
关键词
SARS-CoV-2; COVID-19; Nanostructure materials; Receptor targeting; Inhalation therapeutics; RESPIRATORY SYNDROME CORONAVIRUS; SOLID LIPID NANOPARTICLES; DRUG-DELIVERY SYSTEMS; FUNCTIONAL RECEPTOR; AEROSOL THERAPY; CYTOKINE STORM; SPIKE PROTEIN; VIRUS; VACCINE; CELLS;
D O I
10.1016/j.jddst.2021.102435
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current world health threat posed by the novel coronavirus disease of 2019 (COVID-19) calls for the urgent development of effective therapeutic options. COVID-19 needs daunting routes such as nano-antivirals. Hence, the role of nanotechnology is very critical in combating this nano-enemy "virus." Although substantial resources are under ongoing attention for prevention and care, we would like to start sharing with readers our vision of the role of inhaled nanomaterials and targeting systems that can play an important role in the fight against the COVID-19. In this review, we underline the genomic structure of COVID-19, recent modes of virus transmission with measures to control the infection, pathogenesis, clinical presentation of SARS-CoV-2, and how much the virus affects the lung. Additionally, the recent therapeutic approaches for managing COVID-19 with emphasis on the value of nanomaterial-based technical approaches are discussed in this review. This review also focuses on the safe and efficient delivery of useable targeted therapies using designed nanocarriers. Moreover, the effectiveness and availability of active targeting of certain specific receptors expressed on the coronavirus surfaces via tailored ligand nanoparticles are manipulated. It was also highlighted in this review the role of inhaled medicines including antivirals and repurposed drugs for fighting the associated lung disorders and efficiency of developed vaccines. Moreover, the inhalation delivery safety techniques were also highlighted.
引用
收藏
页数:11
相关论文
共 172 条
[1]   Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19 [J].
Abd Ellah, Noura H. ;
Gad, Sheryhan F. ;
Muhammad, Khalid ;
Batiha, Gaber E. ;
Hetta, Helal F. .
NANOMEDICINE, 2020, 15 (21) :2085-2102
[2]   Nanomedicine as a future therapeutic approach for Hepatitis C virus [J].
Abd Ellah, Noura H. ;
Tawfeek, Hesham M. ;
John, James ;
Hetta, Helal F. .
NANOMEDICINE, 2019, 14 (11) :1471-1491
[3]   A plausible way for excretion of metal nanoparticles via active targeting [J].
Abdellatif, Ahmed A. H. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2020, 46 (05) :744-750
[4]   Cetuximab Conjugated with Octreotide and Entrapped Calcium Alginate-beads for Targeting Somatostatin Receptors [J].
Abdellatif, Ahmed A. H. ;
Ibrahim, Mohamed A. ;
Amin, Mohammed A. ;
Maswadeh, Hamzah ;
Alwehaibi, Muhammed N. ;
Al-Harbi, Sultan N. ;
Alharbi, Zayed A. ;
Mohammed, Hamdoon A. ;
Mehany, Ahmed B. M. ;
Saleem, Imran .
SCIENTIFIC REPORTS, 2020, 10 (01)
[5]   Somatostatin receptors as a new active targeting sites for nanoparticles [J].
Abdellatif, Ahmed A. H. ;
Aldalaen, Sa'ed M. ;
Faisal, Waleed ;
Tawfeek, Hesham M. .
SAUDI PHARMACEUTICAL JOURNAL, 2018, 26 (07) :1051-1059
[6]   Aerosol therapy through high flow nasal cannula in pediatric patients [J].
Al-Subu, Awni M. ;
Hagen, Scott ;
Eldridge, Marlowe ;
Boriosi, Juan .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2017, 11 (12) :945-953
[7]   Membrane binding proteins of coronaviruses [J].
Alsaadi, Entedar A. J. ;
Jones, Ian M. .
FUTURE VIROLOGY, 2019, 14 (04) :275-286
[8]   SARS-CoV-2 Vaccines: Status Report [J].
Amanat, Fatima ;
Krammer, Florian .
IMMUNITY, 2020, 52 (04) :583-589
[9]  
Ameratunga R, 2020, NEW ZEAL MED J, V133, P112
[10]   COVID-19: Time to embrace MDI plus valved-holding chambers! [J].
Amirav, Israel ;
Newhouse, Michael T. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (02) :331-331